Previous Close | 139.23 |
Open | 139.95 |
Bid | 138.49 x 900 |
Ask | 138.53 x 1800 |
Day's Range | 138.43 - 139.99 |
52 Week Range | 103.92 - 142.50 |
Volume | 641,959 |
Avg. Volume | 687,034 |
Market Cap | 12.59B |
Beta (3Y Monthly) | 0.87 |
PE Ratio (TTM) | 43.56 |
EPS (TTM) | 3.18 |
Earnings Date | Jan 21, 2020 - Jan 27, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | 1998-12-02 |
1y Target Est | 141.88 |
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Varian (NYSE: VAR) today announced that its Board of Directors has scheduled the 2020 Annual Meeting of Stockholders for February 13, 2020 with a record date of December 16, 2019. The meeting will be held at the company's headquarters located at 3100 Hansen Way, Palo Alto, CA 94304 at 4:30 p.m. PT.
On Tuesday, Varian Medical Systems got a positive adjustment to its Relative Strength (RS) Rating, from 79 to 82. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
According to the World Health Organization, the number of new cancer cases diagnosed per year in Africa is expected to grow from over 1 million in 2018 to over 2.1 million in 2040. Continuing its program of expanding access to advanced cancer treatments in Africa to help address this issue, Varian (NYSE: VAR) announced the Halcyon™ treatment system has been installed at three additional clinics in the region. The Halcyon radiotherapy system was designed to expand the availability of high-quality cancer care globally and help save the lives of millions more cancer patients.
Varian (NYSE: VAR) today announced Dr. Michelle Le Beau, professor of Medicine, University of Chicago and director, University of Chicago Medicine Comprehensive Cancer Center, has been appointed to the Varian Board of Directors, effective November 27, 2019.
Varian (VAR) gains from Oncology unit, deals with weakness in the Proton Therapy segment.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
PALO ALTO, Calif. , Nov. 22, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced updates to its previously reported GAAP preliminary financial results for its fourth quarter and full fiscal year 2019. There ...
PALO ALTO, Calif. , Nov. 18, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the South Florida Proton Therapy Institute (SFPTI), a Proton International facility, on the campus of Delray Medical ...
PALO ALTO, Calif., Nov. 13, 2019 /PRNewswire/ -- Varian (VAR) today announced for the third year in a row, it was named one of America's Most JUST Companies in 2019, according to the JUST Capital and Forbes magazine JUST 100 List. Varian was ranked number three in the Healthcare Equipment and Services Industry and number 39 on this year's overall list for outperforming its peers in categories like fair pay, ethical leadership, good benefits and work-life balance, equal opportunity, customer treatment and privacy, community support, environmental impact, and delivering shareholder return. The JUST Capital Rankings encompass the 1,000 largest publicly-traded companies in the US and are based on one of the most comprehensive surveys ever conducted on public attitudes toward corporate behavior, involving 9,000 American respondents in 2019 and more than 96,000 over the past six years.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
PALO ALTO, Calif., Nov. 6, 2019 /PRNewswire/ -- In an effort to elevate the patient voice in cancer care, Varian (VAR) announced it has been selected as the vendor of choice by the Michigan Oncology Quality Consortium (MOQC) to support its efforts to develop patient-centered quality measures for cancer care. This year, there were an estimated 58,000 new cancer cases in the state of Michigan, according to the American Cancer Society; nearly 18,000 of those new cases are breast cancer and lung and bronchus cancer.
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Impressive Near-Term Outlook for Medical Instruments Industry
PALO ALTO, Calif., Oct. 30, 2019 /PRNewswire/ -- Icon Group, Australia's largest dedicated provider of cancer care, with a growing reach into New Zealand and Asia, has made a purchase order to further improve the quality of cancer care treatment across its international network. The order includes a significant suite of Varian (VAR) cancer treatment hardware and software, including the first Asia-Pacific purchase of Ethos™ therapy, an Adaptive Intelligence™ solution. Ethos therapy is an artificial intelligence (AI) driven holistic solution designed to increase the capability, flexibility, and efficiency of radiotherapy.
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
PALO ALTO, Calif. , Oct. 29, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced Anshul Maheshwari , vice president and treasurer will take on an expanded role of Investor Relations effective December ...
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.
We believe that Microsoft is one of the best-positioned companies in our coverage to outperform over the next several years. Microsoft is becoming a strategic partner in enterprises’ digital transformations, and key parts of its portfolio (Azure and O365) are serving mission-critical functions. With the unmatched depth and breadth of its technology portfolio, we believe that the company has multiple levers to grow revenue, margins, and its customer base over the next several years, evidenced by multiyear double-digit revenue growth at an unmatched scale.
Q4 2019 Varian Medical Systems Inc Earnings Call
Hershey shares fall despite posting earnings beat Continue reading...
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
Varian (VAR) gains from core Oncology segment's solid contribution in fiscal Q4.